Posted by Michael Wonder on 29 Aug 2023
US FDA approves Bristol Myers Squibb’s Reblozyl (luspatercept-aamt) as first-line treatment of anaemia in adults with lower-risk myelodysplastic syndromes who may require transfusions
28 August 2023 - In a head to head study, results showed Reblozyl nearly doubled the percent of patients achieving primary endpoint of concurrent transfusion independence and haemoglobin increase versus epoetin alfa, with a well-established safety profile.
Bristol Myers Squibb today announced that the US FDA has approved Reblozyl (luspatercept-aamt) for the treatment of anaemia without previous erythropoiesis stimulating agent use in adult patients with very low- to intermediate-risk myelodysplastic syndromes who may require regular red blood cell transfusions.
